An evaluation of the fixed-dose combination sacubitril/valsartan for the treatment of arterial hypertension

References

• Heller DJ, Kishore SP. Closing the blood pressure gap: an affordable proposal to save lives worldwide. BMJ Glob Heal. 2017;2(3):1–4.
   Google Scholar
• Kearney PM, Whelton M, Reynolds K, et al. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004;22(1):11–19.
   Google Scholar
• James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults report from the panel members appointed to the eighth joint national committee (JNC 8). JAMA. 2014;1097(5):507–520.
   Google Scholar
• Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104.
   PubMed Web of Science ®Google Scholar
• Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–967.
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–1913.
   PubMed Web of Science ®Google Scholar
• Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Hypertension. 2018;71(6):e13–e115.
   PubMed Web of Science ®Google Scholar
• Muntner P, Carey RM, Gidding S, et al. Potential US population impact of the 2017 ACC/AHA high blood pressure guideline. Circulation. 2018;137(2):109–118.
   PubMed Web of Science ®Google Scholar
• Gradman AH, Basile JN, Carter BL, et al. Combination therapy in hypertension. J Am Soc Hypertens. 2010;4(2):90–98.
   PubMed Web of Science ®Google Scholar
• Weston A, Absi M, Ward D, et al. Evidence in favor of a calcium-sensing receptor in arterial endothelial cells: studies with calindol and Calhex 231. Circ Res. 2005;97:391–398.
   PubMed Web of Science ®Google Scholar
• Cooper-dehoff RM, Johnson JA. Hypertension pharmacogenomics: in search of personalized treatment approaches. Nat Rev Nephrol. 2017;12(2):110–122.
   Web of Science ®Google Scholar
• Corrao G, Parodi A, Nicotra F, et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens. 2011;29(3):610–618.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399–407.
   PubMed Web of Science ®Google Scholar
• Berhe DF, Taxis K, Haaijer-Ruskamp FM, et al. Impact of adverse drug events and treatment satisfaction on patient adherence with antihypertensive medication – a study in ambulatory patients. Br J Clin Pharmacol. 2017;83(9):2107–2117.
   PubMed Web of Science ®Google Scholar
• Lefort M, Neufcourt L, Pannier B, et al. Sex differences in adherence to antihypertensive treatment in patients aged above 55: the French league against hypertension survey (FLAHS). J Clin Hypertens. 2018;20(10):1–8.
   Web of Science ®Google Scholar
• Gorostidi M, de la Sierra A. Combination therapies for hypertension – why we need to look beyond RAS blockers. Expert Rev Clin Pharmacol. 2018;11(9):841–853.
   PubMed Web of Science ®Google Scholar
• Pottegård A, Hallas J, Olesen M, et al. Hydrochlorothiazide use is strongly associated with risk of lip cancer. J Intern Med. 2017;282(4):322–331.
   PubMed Web of Science ®Google Scholar
• Pedersen SA, Gaist D, Schmidt SAJ, et al. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: a nationwide case-control study from Denmark. J Am Acad Dermatol. 2018;78(4):673–681.
   PubMed Web of Science ®Google Scholar
• Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50(4):401–414.
   PubMed Web of Science ®Google Scholar
• Bevan EG, Connell JM, Doyle J, et al. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens. 1992;10:607–613.
   PubMed Web of Science ®Google Scholar
• Volpe M, Carnovali M, Mastromarino V. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci. 2016;130:57–77.
   PubMed Web of Science ®Google Scholar
• Volpe M. Natriuretic peptides and cardio-renal disease. Int J Cardiol. 2014;176:630–639.
   PubMed Web of Science ®Google Scholar
• Langenickel TH, Dole WP. Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure. Drug Discov Today. 2012;9:e131–e139.
   Google Scholar
• Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: the omapatrilat cardiovascular treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17:103–111.
   PubMed Web of Science ®Google Scholar
• Coats AJ. Omapatrilat–the story of overture and octave. Int J Cardiol. 2002;86(1):1–4.
   PubMed Web of Science ®Google Scholar
• Ksander GM, Ghai RD, deJesus R, et al. Dicarboxylic acid dipeptide neutral endopeptidase inhibitors. J Med Chem. 1995;38(10):1689–1700.
   PubMed Web of Science ®Google Scholar
• Feng L, Karpinski P, Sutton P, et al. LCZ696: a dual-acting sodium supramolecular complex. Tetrahedron Lett. 2012;53(3):275–276.
   Web of Science ®Google Scholar
• Burnier M. Angiotensin II type 1 receptor blockers. Circulation. 2001;103(6):904–912.
   PubMed Web of Science ®Google Scholar
• Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007;370(9583):221–229.
   PubMed Web of Science ®Google Scholar
• Steckelings UM, Kloet A, Sumners C. Centrally mediated cardiovascular actions of the angiotensin II type 2 receptor. Trends Endocrinol Metab. 2017;28(9):684–693.
   PubMed Web of Science ®Google Scholar
• Erdös EG, Skidgel RA. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. Faseb J. 1989;3(2):145–151.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Chappell MC, Brosnihan KB, et al. In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3. 4.24.11)in spontaneously hypertensive rats. Hypertension. 1992;19(6 Pt 2):692–696.
   PubMed Web of Science ®Google Scholar
• Roques BP, Noble F, Daugé V, et al. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev. 1993;45(1);87–146.
   PubMed Web of Science ®Google Scholar
• Ferro CJ, Spratt JC, Haynes WG, et al. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation. 1998;97(23):2323–3230.
   PubMed Web of Science ®Google Scholar
• Campbell DJ. Vasopeptidase inhibition: a double-edged sword? Hypertension. 2003;41(3):383–389.
   PubMed Web of Science ®Google Scholar
• Woodard GE, Rosado JA. Natriuretic peptides in vascular physiology and pathology. Int Rev Cell Mol Biol. 2008;268:59–93.
   PubMed Web of Science ®Google Scholar
• Clerico A, Recchia FA, Passino C, et al. Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am J Physiol Heart Circ Physiol. 2006;290:H17–29.
   PubMed Web of Science ®Google Scholar
• Edwards BS, Zimmerman RS, Schwab TR, et al. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res. 1988;62:191–195.
   PubMed Web of Science ®Google Scholar
• Mangiafico S, Costello-Boerrigter LC, Andersen IA, et al. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J. 2013;34:886–893c.
   PubMed Web of Science ®Google Scholar
• Pandey KN. Emerging roles of natriuretic peptides and their receptors in pathophysiology of hypertension and cardiovascular regulation. J Am Soc Hypertens. 2008;2:210–226.
   PubMed Web of Science ®Google Scholar
• Suga S, Itoh H, Komatsu Y, et al. Cytokine-induced C-type natriuretic peptide (CNP) secretion from vascular endothelial cellsevidence for CNP as a novel autocrine/paracrine regulator from endothelial cells. Endocrinology. 1993;133:3038–3041.
   PubMed Web of Science ®Google Scholar
• Potter LR, Yoder AR, Flora DR, et al. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol. 2009;191:341–366.
   PubMedGoogle Scholar
• Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321–328.
   PubMed Web of Science ®Google Scholar
• Boerrigter G, Burnett JC Jr. Recent advances in natriuretic peptides in congestive heart failure. Expert Opin Investig Drugs. 2004;13:643–652.
   PubMed Web of Science ®Google Scholar
• Zois NE, Bartels ED, Hunter I, et al. Natriuretic peptides in cardiometabolic regulation and disease. Nat Rev Cardiol. 2014;11(7):403–412.
   PubMed Web of Science ®Google Scholar
• Kun A, Kiraly I, Pataricza J, et al. C-type natriuretic peptide hyperpolarizes and relaxes human penile resistance arteries. J Sex Med. 2008;5(5):1114–1125.
   PubMed Web of Science ®Google Scholar
• Rose RA, Giles WR. Natriuretic peptide C receptor signalling in the heart and vasculature. J Physiol. 2008;586:353–366.
   PubMed Web of Science ®Google Scholar
• Fu S, Ping P, Wang F, et al. Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure. J Biol Eng. 2018;12:2.
   PubMed Web of Science ®Google Scholar
• Akahori M, Ayalasomayajula S, Langenickel T, et al. Pharmacokinetics after single ascending dose, food effect, and safety of sacubitril/valsartan (LCZ696), an angiotensin receptor and neprilysin inhibitor, in healthy Japanese subjects. Eur J Drug Metab Pharmacokinet. 2017;42(3):407–416.
   PubMed Web of Science ®Google Scholar
• Kulmatycki K, Langenickel T, Ng D, et al. Pharmacokinetics of single-dose LCZ696 in subjects with mild and moderate hepatic impairment. Clin Pharmacol Drug Dev. 2014;3(Suppl. 1):20.
   Google Scholar
• Han Y, Ayalasomayajula S, Pan W, et al. Pharmacokinetics, safety and tolerability of sacubitril/valsartan (LCZ696) after single-dose administration in healthy chinese subjects. Eur J Drug Metab Pharmacokinet. 2017;42(1):109–116.
   PubMed Web of Science ®Google Scholar
• Ayalasomayajula S, Langenickel TH, Chandra P, et al. Effect of food on the oral bioavailability of the angiotensin receptor – neprilysin inhibitor sacubitril/valsartan (LCZ696) in healthy subjects. Int J Clin Pharmacol Ther. 2016;54(12):1012–1018.
   PubMed Web of Science ®Google Scholar
• Gan L, Jiang X, Mendonza A, et al. Pharmacokinetic drug-drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel-ethinyl estradiol in healthy subjects. Clin Pharmacol Drug Dev. 2016;5(1):27–39.
   PubMed Web of Science ®Google Scholar
• Gan L, Langenickel T, Petruck J, et al. Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor. J Clin Pharmacol. 2016;56(1):78–86.
   PubMed Web of Science ®Google Scholar
• Langenickel TH, Jordaan P, Petruck J, et al. Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization. Eur J Clin Pharmacol. 2016;72(8):917–924.
   PubMed Web of Science ®Google Scholar
• Flarakos J, Du Y, Bedman T, et al. Disposition and metabolism of [14C] sacubitril/valsartan (formerly LCZ696) an angiotensin receptor neprilysin inhibitor, in healthy subjects. Xenobiotica. 2016;46(11):986–1000.
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Dukat A, Böhm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375(9722):1255–1266.
   PubMed Web of Science ®Google Scholar
• Kario K, Sun N, Chiang FT, et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension. 2014;63(4):698–705.
   PubMed Web of Science ®Google Scholar
• Supasyndh O, Sun N, Kario K, et al. Long-term (52-week) safety and efficacy of Sacubitril/valsartan in Asian patients with hypertension. Hypertens Res. 2017;40(5):472–476.
   PubMed Web of Science ®Google Scholar
• Izzo JL Jr, Zappe DH, Jia Y, et al. Efficacy and safety of crystalline valsartan/sacubitril (LCZ696) compared with placebo and combinations of free valsartan and sacubitril in patients with systolic hypertension: the RATIO study. J Cardiovasc Pharmacol. 2017;69(6):374–381.
   PubMed Web of Science ®Google Scholar
• Williams B, Cockcroft JR, Kario K, et al. Effects of sacubitril/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension: the PARAMETER study. Hypertension. 2017;69(3):411–420.
   PubMed Web of Science ®Google Scholar
• Wang TD, Tan RS, Lee HY, et al. Effects of sacubitril/valsartan (LCZ696) on natriuresis, diuresis, blood pressures, and NT-proBNP in salt-sensitive hypertension. Hypertension. 2017;69(1):32–41.
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Wagner F, Mayr M, et al. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study. Eur Heart J. 2017;38(44):3308–3317.
   PubMed Web of Science ®Google Scholar
• Landsberg L, Aronne LJ, Beilin LJ, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of the Obesity Society and the American Society of Hypertension. J Clin Hypertens (Greenwich). 2013;15(1):14–33.
   PubMed Web of Science ®Google Scholar
• Kotsis V1, Stabouli S, Papakatsika S, et al. Mechanisms of obesity-induced hypertension. Hypertens Res. 2010;33(5):386–393.
   PubMed Web of Science ®Google Scholar
• Engeli S, Stinkens R, Heise T, et al. Effect of sacubitril/valsartan on exercise-induced lipid metabolism in patients with obesity and hypertension. Hypertension. 2018;71(1):70–77.
   PubMed Web of Science ®Google Scholar
• Jordan J, Stinkens R, Jax T, et al. Improved insulin sensitivity with angiotensin receptor neprilysin inhibition in individuals with obesity and hypertension. Clin Pharmacol Ther. 2017;101(2):254–263.
   PubMed Web of Science ®Google Scholar
• Huo Y, Li W, Webb R, et al. Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: a randomized, double-blind, 8-week study. J Clin Hypertens (Greenwich). 2019;21(1):67–76.
   PubMed Web of Science ®Google Scholar
• Rakugi H, Kario K, Yamaguchi M, et al. Efficacy and safety of LCZ696 compared with olmesartan in Japanese patients with systolic hypertension. Hypertension. 2014;64:A474.
   Web of Science ®Google Scholar
• Supasyndh O, Wang J, Hafeez K, et al. Efficacy and safety of sacubitril/valsartan (LCZ696) compared with olmesartan in elderly Asian patients (≥65 Years) with systolic hypertension. Am J Hypertens. 2017;30(12):1163–1169.
   PubMed Web of Science ®Google Scholar
• Cheung DG, Aizenberg D, Gorbunov V, et al. Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: a randomized, double-blind, 8-week study. J Clin Hypertens (Greenwich). 2018;20(1):150–158.
   PubMed Web of Science ®Google Scholar
• Kario K, Tamaki Y, Okino N, et al. LCZ696, a first-in-class angiotensin receptor-neprilysin inhibitor: the first clinical experience in patients with severe hypertension. J Clin Hypertens (Greenwich). 2016;18(4):308–314.
   PubMed Web of Science ®Google Scholar
• Ito S, Satoh M, Tamaki Y, et al. Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction. Hypertens Res. 2015;38(4):269–275.
   PubMed Web of Science ®Google Scholar
• Wang JG, Yukisada K, Sibulo A Jr, et al. Efficacy and safety of sacubitril/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy. J Hypertens. 2017;35(4):877–885.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Yu H, Zhao X, et al. The effects of LCZ696 in patients with hypertension compared with angiotensin receptor blockers: a meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther. 2017;22(5):447–457.
   PubMed Web of Science ®Google Scholar
• Malik AH, Aronow WS. Efficacy of sacubitril/valsartan in hypertension. Am J Ther. 2019 Jan 10. [Epub ahead of print]. DOI:10.1097/MJT.0000000000000925.
   Google Scholar
• De Vecchis R, Soreca S, Ariano C. Anti-hypertensive effect of sacubitril/valsartan: a meta-analysis of randomized controlled trials. Cardiol Res. 2019;10(1):24–33.
   PubMed Web of Science ®Google Scholar
• Langenickel TH, Tsubouchi C, Ayalasomayajula S, et al. The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects. Br J Clin Pharmacol. 2016;81(5):878–890.
   PubMed Web of Science ®Google Scholar
• Rose JB, Crews L, Rockenstein E, et al. Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer’s disease. J Neurosci. 2009;29(4):1115–1125.
   PubMed Web of Science ®Google Scholar
• Vodovar N, Paquet C, Mebazaa A, et al. Neprilysin, cardiovascular, and Alzheimer’s diseases: the therapeutic split? Eur Heart J. 2015;36(15):902–905.
   PubMed Web of Science ®Google Scholar
• Campbell DJ. Long-term neprilysin inhibition – implications for ARNIs. Nat Rev Cardiol. 2017;14(3):171–186.
   PubMed Web of Science ®Google Scholar
• Ohno-Matsui K. Parallel findings in age-related macular degeneration and Alzheimer disease. Prog Retin Eye Res. 2011;30(4):217–238.
   PubMed Web of Science ®Google Scholar
• Chrysant SG. Benefits and pitfalls of sacubitril/valsartan treatment in patients with hypertension. J Clin Hypertens (Greenwich). 2018;20(2):351–355.
   PubMed Web of Science ®Google Scholar
• Nielsen PM, Grimm D, Wehland M, et al. The combination of valsartan and sacubitril in the treatment of hypertension and heart failure – an update. Basic Clin Pharmacol Toxicol. 2018;122(1):9–18.
   PubMed Web of Science ®Google Scholar
• Pini R, Cavallini MC, Palmieri V, et al. Central but not brachial blood pressure predicts cardiovascular events in an unselected geriatric population: the ICARe dicomono study. J Am Coll Cardiol. 2008;51:2432‐2439.
   PubMed Web of Science ®Google Scholar
• Ibsen H, Olsen MH, Wachtell K, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension. 2005;45(2):198–202.
   PubMed Web of Science ®Google Scholar
• Takagi H, Yamamoto H, Iwata K, et al. Effects of telmisartan on proteinuria or albuminuria: a meta-analysis of randomized trials. Int J Cardiol. 2013;167(4):1443–1449.
   PubMed Web of Science ®Google Scholar
• Haynes R, Judge PK, Staplin N, et al. Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease. Circulation. 2018;138(15):1505–1514.
   PubMed Web of Science ®Google Scholar
• UK HARP-III Collaborative Group. Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom heart and renal protection (HARP)- III-rationale, trial design and baseline data. Nephrol Dial Transplant. 2017;32(12):2043–2051.
   PubMed Web of Science ®Google Scholar
• Calhoun DA, Lacourcière Y, Chiang YT, et al. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension. 2009;54(1):32–39.
   PubMed Web of Science ®Google Scholar